ライフサイエンスコーパス: cytogenetic abnormality

1 ide; each patient had trisomy 13 as the sole cytogenetic abnormality.

2 atients with lower-risk MDS with the del(5q) cytogenetic abnormality.

3 s-CMD) characterized by the t(5;12)(q33;p13) cytogenetic abnormality.

4 osome 5q deletion with or without additional cytogenetic abnormalities.

5 opoiesis and an increase in the incidence of cytogenetic abnormalities.

6 al characteristics, pathologic features, and cytogenetic abnormalities.

7 ability to secondary recipients; and lack of cytogenetic abnormalities.

8 for severe X-linked diseases or X-chromosome cytogenetic abnormalities.

9 h long latency, low penetrance, and acquired cytogenetic abnormalities.

10 ave pronounced chromosome breakage and other cytogenetic abnormalities.

11 groups, including in patients with high-risk cytogenetic abnormalities.

12 with Fanconi anemia universally bear complex cytogenetic abnormalities.

13 somy 8 was associated with other unfavorable cytogenetic abnormalities.

14 me 13, deletion of Y chromosome, and complex cytogenetic abnormalities.

15 6.2%) were normal, and 434 (51.1%) had other cytogenetic abnormalities.

16 ns with increasingly shortened telomeres and cytogenetic abnormalities.

17 ridization (FISH) were used to detect clonal cytogenetic abnormalities.

18 Medulloblastomas exhibit an array of diverse cytogenetic abnormalities.

19 al or environmental exposure and presence of cytogenetic abnormalities.

20 the high proportion of patients with adverse cytogenetic abnormalities.

21 s defined by a combination of morphology and cytogenetic abnormalities.

22 s; in contrast, leiomyomas have simple or no cytogenetic abnormalities.

23 Five patients had previously undiagnosed cytogenetic abnormalities.

24 re similar for the patients with and without cytogenetic abnormalities.

25 blasts or any specific type of leukemia cell cytogenetic abnormalities.

26 g-term continuous CR for patients with other cytogenetic abnormalities.

27 ding the prognostic implications of specific cytogenetic abnormalities.

28 al karyotype AML, and 88 patients with other cytogenetic abnormalities.

29 lecular basis, characterized by nonrecurrent cytogenetic abnormalities.

30 ion was found in five of 15 patients who had cytogenetic abnormalities.

31 ive therapy, but none were the patients with cytogenetic abnormalities.

32 ot able to overcome the adverse prognosis of cytogenetic abnormalities.

33 igh percentage of MDS HSC (92% +/- 4%) carry cytogenetic abnormalities.

34 al and clinical significance of the observed cytogenetic abnormalities.

35 roves the poor PFS associated with high-risk cytogenetic abnormalities.

36 dary molecular events, as well as additional cytogenetic abnormalities.

37 nto the effect of new drugs in patients with cytogenetic abnormalities.

38 g a diploid karyotype or other miscellaneous cytogenetic abnormalities (14.2 pg/mL; P <.001).

39 d in the genetic etiology of AD based on (1) cytogenetic abnormalities; (2) increased recombination f

40 (.38 and.37) and patients with miscellaneous cytogenetic abnormalities (.52 and.49; P <.001 for each

41 re with the highest proportion of detectable cytogenetic abnormalities (76%; including 83% of all fav

42 other B-NHL cell lines examined with 12q24.1 cytogenetic abnormalities, a mediastinal B-NHL cell line

43 remission (CR); three of three patients with cytogenetic abnormalities achieved cytogenetic CR (none

44 Deletion 17p or 6q with or without other cytogenetic abnormalities, age at least 60 years, beta2-

45 was no common immunophenotype or consistent cytogenetic abnormality, although all showed structural

46 cytogenetic results; 137 (25%) had high-risk cytogenetic abnormalities and 172 (32%) had 1q21 amplifi

47 in, and mice lacking both Suv39-h genes show cytogenetic abnormalities and an increased incidence of

48 determine whether miRNAs are associated with cytogenetic abnormalities and clinical features in acute

49 All cultures contain cytogenetic abnormalities and elevated flow-cytometric 4

50 tic syndromes (MDS) have high frequencies of cytogenetic abnormalities and evidence is accumulating o

51 Based on outcome for specific cytogenetic abnormalities and karyotype complexity, pati

52 F, we retrospectively examined the impact of cytogenetic abnormalities and karyotypic evolution on th

53 One such locus is on chromosome 7p, where cytogenetic abnormalities and loss of heterozygosity (LO

54 Human chromosome 3p cytogenetic abnormalities and loss of heterozygosity hav

55 ene expression data is used to identify both cytogenetic abnormalities and molecular pathways that ar

56 ed on multivariable Cox regression analyses, cytogenetic abnormalities and mutations in RUNX1, NRAS,

57 These cytogenetic abnormalities and mutations lead to increase

58 ng Fancc(-/-) cells have a high incidence of cytogenetic abnormalities and myeloid malignancies that

59 Superseding the adverse effects of cytogenetic abnormalities and other standard prognostic

60 C clone probably contributes to the frequent cytogenetic abnormalities and poor responses to chemothe

61 th multiple myeloma is dictated primarily by cytogenetic abnormalities and proliferative capacity of

62 major classes of constitutional, structural cytogenetic abnormalities and recent studies that explor

63 The relationship between specific cytogenetic abnormalities and response to treatment was

64 n analysis of 42 leukemia cases with various cytogenetic abnormalities and several normal controls, t

65 risk" group, defined as those with high-risk cytogenetic abnormalities and/or 1q21 amplification (HR,

66 Patients of all ages with very-bad-risk cytogenetic abnormalities and/or FLT3-ITD (internal tand

67 n patients with AML and trisomy 11 as a sole cytogenetic abnormality and in 11% of patients with AML

68 ression induces centrosome amplification and cytogenetic abnormalities, and (2) in Ph(+) CML, it syne

69 Dupriez score, cytogenetic abnormalities, and degree of marrow fibrosis

70 Of adults with de novo AML, 45% lack cytogenetic abnormalities, and identification of predict

71 impact in AML with CK, AML with MDS-related cytogenetic abnormalities, and in a revised definition (

72 Cytogenetic abnormalities appear to be increased in chil

73 Clonal cytogenetic abnormalities are a major risk factor for re

74 t duration of response to therapy or adverse cytogenetic abnormalities are associated with a poor out

75 Certain cytogenetic abnormalities are associated with increased

76 Cytogenetic abnormalities are important clinical paramet

77 Although cytogenetic abnormalities are important prognostic facto

78 Cytogenetic abnormalities are increased in schizophrenia

79 Certain cytogenetic abnormalities are known to adversely impact

80 In acute myeloid leukemia (AML), cytogenetic abnormalities are present in more than half

81 In pediatric acute myeloid leukemia (AML), cytogenetic abnormalities are strong indicators of progn

82 The roles of cytogenetic abnormalities as well as aberrant angiogenes

83 samples were evaluated for the occurrence of cytogenetic abnormalities as well as the expression leve

84 transplantation is critically determined by cytogenetic abnormalities, as previously defined by Inte

85 ble-region heavy chain gene mutation status, cytogenetic abnormalities assessed by fluorescent in sit

86 GHV) gene mutation status, CD49d status, and cytogenetic abnormalities assessed by interphase fluores

87 e 21 (AML1-ETO), is one of the most frequent cytogenetic abnormalities associated with acute myelogen

88 l anomalies represent one of the most common cytogenetic abnormalities associated with these diseases

89 Patients with AML and MDS who had cytogenetic abnormalities associated with unfavorable ri

90 lthough only one patient had the most common cytogenetic abnormality associated with secondary MDS/AL

91 l acute lymphoid leukemia without structural cytogenetic abnormalities at 11q23 and 9p22.

92 Cytogenetic abnormalities at chromosome 1q21 are among t

93 Patients with cytogenetic abnormalities at CR (n = 71) had significant

94 In multivariate analysis, persistent cytogenetic abnormalities at CR was an independent predi

95 = .001), but among patients with persistent cytogenetic abnormalities at CR, no significant differen

96 Among the patients with persistent cytogenetic abnormalities at CR, those who underwent SCT

97 Lymphadenopathy > or = 5 cm, but not cytogenetic abnormalities at HCT, predicted relapse.

98 dies have shown a loss of heterozygosity and cytogenetic abnormalities at the 3p region in ovarian, e

99 Risk for cytogenetic abnormalities based on features and size: sm

100 Four of seven evaluable responders with cytogenetic abnormalities before treatment had normal cy

101 Nineteen of 99 tumors with complex cytogenetic abnormalities, but none of 69 tumors with si

102 intact Arf-p53 pathway, and did not display cytogenetic abnormalities by spectral karyotyping (SKY)

103 thalidomide arm in the one third exhibiting cytogenetic abnormalities (CA).

104 The presence of a metaphase cytogenetic abnormality (CA) is the key negative predict

105 Cytogenetic abnormalities (CAs) and more than seven FLs

106 Metaphase cytogenetic abnormalities (CAs), especially of chromosom

107 Among the prognostic factors evaluated, cytogenetic abnormalities (CAs), which are present in on

108 nce for the one third of patients exhibiting cytogenetic abnormalities (CAs; P = .02), a well-recogni

109 Certain cytogenetic abnormalities common in AML may affect apopt

110 Detailed genomic studies have shown that cytogenetic abnormalities contribute to multiple myeloma

111 isease as well as in patients with high-risk cytogenetic abnormalities, defined as t(4;14), t(14;16),

112 All enrolled participants had high-risk cytogenetic abnormalities (deletion 17p, TP53 mutation,

113 three prognostic groups could be defined by cytogenetic abnormalities detected at presentation in co

114 s clinical trial confirms prospectively that cytogenetic abnormalities detected by FISH can predict o

115 Retrospective studies suggest cytogenetic abnormalities detected by interphase fluores

116 The presence of additional cytogenetic abnormalities did not modify the outcome of

117 Patients with multiple adverse cytogenetic abnormalities do not benefit from these agen

118 Several patients acquired additional clonal cytogenetic abnormalities during therapy, a finding with

119 For inv(16) AML, secondary cytogenetic abnormalities (especially +22) and male sex

120 nt, and treatment parameters showed that six cytogenetic abnormalities (ETV6-RUNX1, high hyperdiploid

121 Cytogenetic abnormalities; expression levels of the miR-

122 roup of acute myeloid leukemias with various cytogenetic abnormalities, failed to reveal MLF2 gene re

123 All eight patients who presented with cytogenetic abnormalities (five chromosome 5 or 7 abnorm

124 ous chromosomes are among the most prevalent cytogenetic abnormalities found in cancer cells.

125 of changes that recapitulates, in part, the cytogenetic abnormalities found in human APL.

126 condary mutations recapitulate, in part, the cytogenetic abnormalities found in human APL.

127 nosomy of chromosome 7 was the most frequent cytogenetic abnormality, found in 24% of patients.

128 rmalities, but none of 69 tumors with simple cytogenetic abnormalities, had mutations (P < .001).

129 A range of cytogenetic abnormalities has been detected in patterned

130 ukemia where the identification of nonrandom cytogenetic abnormalities has paved the way for the disc

131 Other clonal cytogenetic abnormalities have also been reported in the

132 Unique and shared cytogenetic abnormalities have been documented for margi

133 Cytogenetic abnormalities have been identified that allo

134 Bone marrow cytogenetic abnormalities have been observed among survi

135 r OS, independent of other factors including cytogenetic abnormalities (hazard ratio 1.51, P = .049).

136 The acquisition of the cytogenetic abnormalities hyperdiploidy or translocation

137 Studies indicate that specific cytogenetic abnormalities, identified by classical G-ban

138 he impact of the four most common interphase cytogenetic abnormalities in 28 CLL patients relative to

139 we aimed to reassess the prognostic value of cytogenetic abnormalities in a large series of 617 adult

140 TO translocation is one of the most frequent cytogenetic abnormalities in acute myeloid leukemia (AML

141 erarchial classification system for specific cytogenetic abnormalities in acute myeloid leukemia (AML

142 t(16;16)(p13.1;q22), one of the most common cytogenetic abnormalities in AML, leads to expression of

143 ion with one of the most frequently observed cytogenetic abnormalities in AML, the t(8;21)(q22;q22) t

144 Moreover, the most common recurrent cytogenetic abnormalities in ASD involve maternally deri

145 We have improved our understanding of the cytogenetic abnormalities in CLL and soon may see identi

146 Further definition of common cytogenetic abnormalities in CLL make it appear that the

147 ome 7 and del(7q) [-7/del(7q)] are recurring cytogenetic abnormalities in hematologic malignancies, i

148 The cytogenetic abnormalities in lymphocytes are exuberant:

149 usion requirements and reverse cytologic and cytogenetic abnormalities in patients who have the myelo

150 We developed a model to predict cytogenetic abnormalities in patients with multiple myel

151 The occurrence of cytogenetic abnormalities in patients years after presen

152 Dynamic prognostic significance of cytogenetic abnormalities in PMF should be further prosp

153 peractivation, centrosome amplification, and cytogenetic abnormalities in the bone marrow (BM).

154 correlate the gene expression profiles with cytogenetic abnormalities in these DLBCLs, we examined t

155 Cytogenetic abnormalities in these tumors are consistent

156 nt partner chromosomes represent a recurrent cytogenetic abnormality in B-cell non-Hodgkin's lymphoma

157 Trisomy 8 is a frequent cytogenetic abnormality in bone marrow cells in patients

158 usually associated with the appearance of a cytogenetic abnormality in bone marrow cells.

159 The 8;21 translocation is the most common cytogenetic abnormality in human acute myelogenous leuke

160 f chromosome 5q (del[5q]) is the most common cytogenetic abnormality in MDS.

161 The subsequent development of a clonal cytogenetic abnormality in nonrevertant cells suggests t

162 %) had trisomy 21 (or mosaicism) as the only cytogenetic abnormality in the blast cells.

163 ally monosomy 7 and trisomy 8, is a frequent cytogenetic abnormality in the myelodysplastic syndromes

164 Leiomyosarcomas typically have complex cytogenetic abnormalities; in contrast, leiomyomas have

165 The cytogenetic abnormalities included a deletion of all or

166 had a diploid karyotype and one had multiple cytogenetic abnormalities including monosomy 5 and 7.

167 2 years, relapse occurred in 2 patients, and cytogenetic abnormalities (including monosomy 7) were ob

168 The other cytogenetic abnormalities, including complex and monosom

169 There are frequent cytogenetic abnormalities, including deletions of chromo

170 t across subgroups with individual high-risk cytogenetic abnormalities, including patients with del(1

171 of leukemias frequently defined by recurrent cytogenetic abnormalities, including rearrangements invo

172 is a B-cell malignancy stratified in part by cytogenetic abnormalities, including the high-risk copy

173 Various cytogenetic abnormalities, including those associated wi

174 d lymphoid cells that contained molecular or cytogenetic abnormalities indicating their malignant nat

175 Expression signatures for AML with cytogenetic abnormalities involving -5 or -7 were simila

176 the study of children with lissencephaly and cytogenetic abnormalities involving chromosome 17p, howe

177 A variety of cytogenetic abnormalities involving chromosome 7 have be

178 Two of six DPL lesions karyotyped had cytogenetic abnormalities involving chromosomes 7, 12, a

179 Identification of cytogenetic abnormalities is an important clue for the e

180 Although detection of any cytogenetic abnormality is considered to suggest higher-

181 Identification of the specific cytogenetic abnormality is one of the critical steps for

182 Turner syndrome, one of the most common cytogenetic abnormalities, is characterised by complete

183 e that other biologic characteristics beyond cytogenetic abnormalities likely play a role in this dis

184 e immune-modulatory agents to MDS-associated cytogenetic abnormalities (MDS-CA) and clinical MDS or a

185 MDS-associated cytogenetic abnormalities (MDS-CAs) were observed in 105

186 long-term survival for patients with FA with cytogenetic abnormalities, MDS, or acute leukemia is ach

187 Monosomy 3 of the primary tumor is the cytogenetic abnormality most strongly associated with th

188 outcomes in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome (MDS

189 e analyzed data on 113 patients with FA with cytogenetic abnormalities (n = 54), MDS (n = 45), or acu

190 inv(16)(p13q22) is one of the most frequent cytogenetic abnormalities observed in acute myeloid leuk

191 In 9 of 12 cases, the same cytogenetic abnormality observed at the time of MDS diag

192 tions of chromosome 7q to be the most common cytogenetic abnormality observed in SLVL, a leukemic var

193 The inv(16)(p13q22) and t(16;16)(p13;q22) cytogenetic abnormalities occur commonly in acute myeloi

194 Cytogenetic abnormalities of chromosome arm 9p occur fre

195 6.3, a region reported to be associated with cytogenetic abnormalities of obese patients.

196 isorders known to be caused by molecular and cytogenetic abnormalities of the proximal short arm of c

197 of segment 17q21-qter) is the most frequent cytogenetic abnormality of neuroblastoma cells.

198 ospectively studied the prognostic impact of cytogenetic abnormalities on a larger cohort of patients

199 (AML) to ascertain the prognostic impact of cytogenetic abnormalities on complete remission (CR) rat

200 onresponders and 2 responders, developed new cytogenetic abnormalities on eltrombopag, including 5 wi

201 nfounding effects of this preexisting marrow cytogenetic abnormality on the response to gene transfer

202 ched related donor transplantations who have cytogenetic abnormalities only have the best survival.

203 ], respectively; P < .001) and patients with cytogenetic abnormalities only versus MDS/acute leukemia

204 cases of AML and in cases with +11 as a sole cytogenetic abnormality, only one chromosome contains th

205 The rest of the patients had nonspecific cytogenetic abnormalities or lacked cytogenetic informat

206 multiple myeloma (MM) patients regardless of cytogenetic abnormalities or response to current treatme

207 ranulocyte count, the presence of additional cytogenetic abnormalities, or the presence of extramedul

208 Patients with cytogenetic abnormalities other than t(9;22), t(4;11), -

209 otype (CK), and myelodysplasia (MDS)-related cytogenetic abnormalities (P < .0001, each); and NPM1 mu

210 ALC less than 5 x 10(9)/L had lower rates of cytogenetic abnormalities (P = .0002) and higher rates o

211 have resulted in increased identification of cytogenetic abnormalities, particularly the presence of

212 for evolution to acute myeloid leukemia were cytogenetic abnormalities, percentage of BM myeloblasts,

213 red cell aplasia, (2) the presence of clonal cytogenetic abnormality predicts poor response to immuno

214 and further characterization of some of the cytogenetic abnormalities present in this disease.

215 e loss of chromosome 7q (del(7q)), a somatic cytogenetic abnormality present in myelodysplastic syndr

216 ivariate analysis of pretreatment variables, cytogenetic abnormalities, present in 47% of patients wi

217 nfections is associated with myelodysplasia, cytogenetic abnormalities, pulmonary alveolar proteinosi

218 ognostic significance of many rare recurring cytogenetic abnormalities remains uncertain.

219 The cytogenetic abnormalities reported in this group of brea

220 ient exhibited an unclassified leukemia with cytogenetic abnormalities resulting in monosomy for 7p a

221 ion between 13q12 and 8p11 is the consistent cytogenetic abnormality seen in a nonspecific myeloproli

222 hen the prognostic impact of race, secondary cytogenetic abnormalities, sex, and response to salvage

223 increased beta2-microglobulin, patients with cytogenetic abnormalities such as chromosome 13 deletion

224 Select cytogenetic abnormalities such as del(17)(p13.1) and del

225 ltiple myeloma based on cytogenetics Several cytogenetic abnormalities such as t(4;14), del(17/17p),

226 Some recurrent cytogenetic abnormalities, such as t(8;16)(p11;p13), are

227 The presence of certain high-risk cytogenetic abnormalities, such as translocations (4;14)

228 dy with TRF less than 5.0 kb, 3 had acquired cytogenetic abnormalities, suggesting that telomere eros

229 searchers have focused on characterizing the cytogenetic abnormalities that are detectable by routine

230 ions of 7q are recurring leukemia-associated cytogenetic abnormalities that correlate with adverse ou

231 complex hyperdiploid karyotypes and diverse cytogenetic abnormalities that included recurring and no

232 has been shown that in some patients without cytogenetic abnormalities the otherwise repressed matern

233 cluding age, mutations in FLT3 and NPM1, and cytogenetic abnormalities, the HRs for LSC score in the

234 way abnormalities can be linked to predicted cytogenetic abnormalities to identify likely candidate g

235 The incidence of secondary cytogenetic abnormalities was 32%.

236 ll transplantation, but no unique pattern of cytogenetic abnormalities was observed.

237 The prognostic significance of each specific cytogenetic abnormality was not assessable.

238 ned poor-risk group with few known recurring cytogenetic abnormalities, we performed gene expression

239 normal karyotype, 824 patients with AML with cytogenetic abnormalities were analyzed.

240 Complex cytogenetic abnormalities were associated with poorer su

241 nd risk factor measures of the subjects with cytogenetic abnormalities were compared with those of th

242 High-risk cytogenetic abnormalities were defined as del(17p), t(4;

243 The most frequently observed cytogenetic abnormalities were loss of 3p (60%), gain of

244 The most common cytogenetic abnormalities were monosomy 7 or del(7q) (53

245 Complex cytogenetic abnormalities were present in all patients.

246 horter OS than whites when certain secondary cytogenetic abnormalities were present.

247 nal status was significant for both, whereas cytogenetic abnormalities were significant only for OS.

248 in situ hybridization for leukemia-specific cytogenetic abnormalities (when present) and by transpla

249 ude that tumor endothelial cells can acquire cytogenetic abnormalities while in the tumor microenviro

250 osis (MBL) shares common immunophenotype and cytogenetic abnormalities with CLL, from which it is dis

251 their individual prognostic impact, specific cytogenetic abnormalities with more than or equal to 5 i